Sanuwave Health, Inc. Updates Second Quarter 2026 Guidance

Sanuwave Health, Inc. has announced updated revenue guidance for the second quarter of 2026, projecting revenues between $8.5 to $9.5 million. This revised guidance is below the company's previous forecast due to significant changes in the capital equipment market for their Ultramist system. The company cited widespread clawbacks of CMS reimbursement for skin substitutes and allografts, leading to financial distress and closures of some wound care practices. This has resulted in a secondary market for used Ultramist systems, negatively impacting new system sales. Despite these challenges, Sanuwave expects a record quarter for applicator unit sales. The company plans to focus on qualifying, training, and supporting new users, particularly those acquiring systems through the secondary market, to ensure patient care standards and drive consumable revenue. Sanuwave remains optimistic about its long-term potential but acknowledges near-term challenges in capital sales.